Literature DB >> 10548595

Sterols of Pneumocystis carinii hominis organisms isolated from human lungs.

E S Kaneshiro1, Z Amit, J Chandra, R P Baughman, C Contini, B Lundgren.   

Abstract

The opportunistic pathogen Pneumocystis carinii causes pneumonia (P. carinii pneumonia, or PCP) in immunocompromised individuals such as AIDS patients. Rat-derived P. carinii carinii organisms have distinct sterols which are not synthesized by mammals and not found in other microbes infecting mammalian lungs. The dominant sterol present in the organism is cholesterol (which is believed to be scavenged from the host), but other sterols in P. carinii carinii have an alkyl group at C-24 of the sterol side chain (C(28) and C(29) 24-alkylsterols) and a double bond at C-7 of the nucleus. Recently, pneumocysterol (C(32)), which is essentially lanosterol with a C-24 ethylidene group, was detected in lipids extracted from a formalin-fixed human P. carinii-infected lung, and its structures were elucidated by gas-liquid chromatography, mass spectrometry, and nuclear magnetic resonance spectrometry in conjunction with analyses of chemically synthesized authentic standards. The sterol composition of isolated P. carinii hominis organisms has yet to be reported. If P. carinii from animal models is to be used for identifying potential drug targets and for developing chemotherapeutic approaches to clear human infections, it is important to determine whether the 24-alkylsterols of organisms found in rats are also present in organisms in humans. In the present study, sterol analyses of P. carinii hominis organisms isolated from cryopreserved human P. carinii-infected lungs and from bronchoalveolar lavage fluid were performed. Several of the same distinct sterols (e.g., fungisterol and methylcholest-7-ene-3beta-ol) previously identified in P. carinii carinii were also present in organisms isolated from human specimens. Pneumocysterol was detected in only some of the samples.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548595      PMCID: PMC95807          DOI: 10.1128/CDLI.6.6.970-976.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  28 in total

1.  Pneumocystis carinii: new separation method from lung tissue.

Authors:  P D Walzer; M E Rutledge; K Yoneda; B J Stahr
Journal:  Exp Parasitol       Date:  1979-06       Impact factor: 2.011

2.  Antimicrobial susceptibility of Pneumocystis carinii in culture.

Authors:  M S Bartlett; R Eichholtz; J W Smith
Journal:  Diagn Microbiol Infect Dis       Date:  1985-09       Impact factor: 2.803

Review 3.  Molecular biology and epidemiology of Pneumocystis carinii infection in AIDS.

Authors:  J R Stringer; P D Walzer
Journal:  AIDS       Date:  1996-06       Impact factor: 4.177

4.  Infection with Pneumocystis carinii is prevalent in healthy Gambian children.

Authors:  A E Wakefield; T J Stewart; E R Moxon; K Marsh; J M Hopkin
Journal:  Trans R Soc Trop Med Hyg       Date:  1990 Nov-Dec       Impact factor: 2.184

5.  Semiquantitative technique for estimating Pneumocystis carinii burden in the lung.

Authors:  R P Baughman; S Strohofer; G Colangelo; P T Frame
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

6.  Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis.

Authors:  S P Keely; J R Stringer; R P Baughman; M J Linke; P D Walzer; A G Smulian
Journal:  J Infect Dis       Date:  1995-08       Impact factor: 5.226

7.  Serologic responses to Pneumocystis carinii antigens in health and disease.

Authors:  S L Peglow; A G Smulian; M J Linke; C L Pogue; S Nurre; J Crisler; J Phair; J W Gold; D Armstrong; P D Walzer
Journal:  J Infect Dis       Date:  1990-02       Impact factor: 5.226

8.  Pneumocystis carinii infection: evidence for high prevalence in normal and immunosuppressed children.

Authors:  L L Pifer; W T Hughes; S Stagno; D Woods
Journal:  Pediatrics       Date:  1978-01       Impact factor: 7.124

9.  Bronchoscopy with bronchoalveolar lavage in tuberculosis and fungal infections.

Authors:  R P Baughman; M N Dohn; R G Loudon; P T Frame
Journal:  Chest       Date:  1991-01       Impact factor: 9.410

10.  Surfactant phospholipids and lavage phospholipase A2 in experimental Pneumocystis carinii pneumonia.

Authors:  P M Sheehan; D C Stokes; Y Y Yeh; W T Hughes
Journal:  Am Rev Respir Dis       Date:  1986-09
View more
  7 in total

1.  Heterogeneity of Pneumocystis sterol profiles of samples from different sites in the same pair of lungs suggests coinfection by distinct organism populations.

Authors:  Z Amit; E S Kaneshiro
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

2.  C27 to C32 sterols found in Pneumocystis, an opportunistic pathogen of immunocompromised mammals.

Authors:  E S Kaneshiro; M A Wyder
Journal:  Lipids       Date:  2000-03       Impact factor: 1.880

3.  Inhibitors of sterol biosynthesis and amphotericin B reduce the viability of pneumocystis carinii f. sp. carinii.

Authors:  E S Kaneshiro; M S Collins; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 4.  Sterol metabolism in the opportunistic pathogen Pneumocystis: advances and new insights.

Authors:  Edna S Kaneshiro
Journal:  Lipids       Date:  2004-08       Impact factor: 1.880

Review 5.  PCR-based diagnosis of human fungal infections.

Authors:  Prasanna D Khot; David N Fredricks
Journal:  Expert Rev Anti Infect Ther       Date:  2009-12       Impact factor: 5.091

Review 6.  A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.

Authors:  Liang Ma; Ousmane H Cissé; Joseph A Kovacs
Journal:  Clin Microbiol Rev       Date:  2018-06-13       Impact factor: 26.132

7.  Δ(24)-Sterol Methyltransferase Plays an Important Role in the Growth and Development of Sporothrix schenckii and Sporothrix brasiliensis.

Authors:  Luana P Borba-Santos; Gonzalo Visbal; Thalita Gagini; Anderson M Rodrigues; Zoilo P de Camargo; Leila M Lopes-Bezerra; Kelly Ishida; Wanderley de Souza; Sonia Rozental
Journal:  Front Microbiol       Date:  2016-03-11       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.